價(jià)格 | ¥1138 | ¥1880 |
包裝 | 50ul | 100ul |
最小起訂量 | 50ul |
發(fā)貨地 | 上海 |
更新日期 | 2024-11-06 |
中文名稱:Anti-Cytokeratin 19 antibody-人細(xì)胞角蛋白19單克隆抗體 | 英文名稱:Cytokeratin 19 |
品牌: 滬震生物 | 產(chǎn)地: 中國(guó)/上海 |
保存條件: -20°C | 純度規(guī)格: > 99% |
產(chǎn)品類別: 抗體 一抗 | |
抗體名: 40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_HUMAN; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd | 靶點(diǎn): 詳見(jiàn)說(shuō)明書(shū) |
宿主: Mouse | 適應(yīng)物種: 詳見(jiàn)說(shuō)明書(shū) |
克隆性: 詳見(jiàn)說(shuō)明書(shū) | 濃度: 1mg/ml |
應(yīng)用范圍: IHC-P=1:200-800 IHC-F=1:200-800 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. | 標(biāo)識(shí)物: 詳見(jiàn)說(shuō)明書(shū) |
形態(tài): 液體 | 亞型: IgG1 |
免疫原: 詳見(jiàn)說(shuō)明書(shū) | 貨號(hào): BH0003 |
用途范圍: 科研使用 | 規(guī)格: 50ul/100ul/200ul |
是否進(jìn)口: 否 | 是否單克隆: 詳見(jiàn)說(shuō)明書(shū)p55 |
保質(zhì)期: 12個(gè)月 | 抗原來(lái)源: 詳見(jiàn)說(shuō)明書(shū) |
標(biāo)記物: 詳見(jiàn)說(shuō)明書(shū) | 產(chǎn)品用途: IHC-P=1:200-800 IHC-F=1:200-800 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
Host:Mouse
Target Protein:Cytokeratin 19
IR:Immunogen Range:
Clonality:Monoclonal
Isotype:IgG
Entrez Gene:3880
Swiss Prot:P08727
Source:KLH conjugated synthetic peptide derived from human Cytokeratin 19:
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:Due to its high sensitivity, KRT19 is the most used marker for the RT-PCR-mediated detection of tumor cells disseminated in lymph nodes, peripheral blood, and bone marrow of breast cancer patients. Depending on the assays, KRT19 has been shown to be both a specific and a non-specific marker. False positivity in such KRT19 RT-PCR studies include: illegitimate transcription (expression of small amounts of KRT19 mRNA by tissues in which it has no real physiological role), haematological disorders (KRT19 induction in peripheral blood cells by cytokines and growth factors, which circulate at higher concentrations in inflammatory conditions and neutropenia), the presence of pseudogenes (two KRT19 pseudogenes, KRT19a and KRT19b, have been identified, which have significant sequence homology to KRT19 mRNA. Moreover, Ck-19 is widely applied as post-operative diagnostic marker of papillary thyroid carcinoma.
Size:50ul
Concentration:
Applications:IHC-P(1:200-800)
IHC-F(1:200-800)
Cross Reactive Species:Human
本產(chǎn)品僅供科研使用。不能用于人和動(dòng)物治療等其它臨床診斷用!
成立日期 | 2014-05-08 (11年) | 注冊(cè)資本 | 100萬(wàn)元整 |
員工人數(shù) | 10-50人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,細(xì)胞培養(yǎng),蛋白組學(xué),分子生物學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
珠海啟尼亞生物技術(shù)有限公司
|
2020-01-16 | ||
詢價(jià) |
濟(jì)南博航科學(xué)儀器有限公司
|
2020-01-16 | ||
詢價(jià) |
北京柏奧易思生物科技有限公司
|
2020-01-15 | ||
¥800 |
希施生物科技(上海)有限公司
|
2020-01-15 | ||
¥4560 |
上海恪敏生物科技有限公司
|
2020-01-13 |